
A BILL FOR AN ACT

RELATING TO CONTROLLED SUBSTANCES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended to read as follows:

3 "§329-14 **Schedule I.** (a) The controlled substances
4 listed in this section are included in schedule I.

5 (b) Any of the following opiates, including their isomers,
6 esters, ethers, salts, and salts of isomers, esters, and ethers,
7 unless specifically excepted, whenever the existence of these
8 isomers, esters, ethers, and salts is possible within the
9 specific chemical designation:

- 10 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
11 phenethyl)-4-piperidinyl]-N-phenylacetamide);
12 (2) Acetylmethadol;
13 (3) Allylprodine;
14 (4) Alphacetylmethadol (except levo-alphacetylmethadol,
15 levomethadyl acetate, or LAAM);
16 (5) Alphameprodine;
17 (6) Alphamethadol;

- 1 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
- 2 phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
- 3 2-phenylethyl)-4-(N-propanilido) piperidine);
- 4 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
- 5 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 6 (9) Benzethidine;
- 7 (10) Betacetylmethadol;
- 8 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
- 9 piperidinyl]-N-phenylpropanamide);
- 10 (12) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
- 11 phenethyl)-3-methyl-4-piperidinyl]-N-
- 12 phenylpropanamide);
- 13 (13) Betameprodine;
- 14 (14) Betamethadol;
- 15 (15) Betaprodine;
- 16 (16) Clonitazene;
- 17 (17) Dextromoramide;
- 18 (18) Diampromide;
- 19 (19) Diethylthiambutene;
- 20 (20) Difenoxyin;
- 21 (21) Dimenoxadol;
- 22 (22) Dimepheptanol;

- 1 (23) Dimethylthiambutene;
- 2 (24) Dioxaphetyl butyrate;
- 3 (25) Dipipanone;
- 4 (26) Ethylmethylthiambutene;
- 5 (27) Etonitazene;
- 6 (28) Etoxeridine;
- 7 (29) Furethidine;
- 8 (30) Hydroxypethidine;
- 9 (31) Ketobemidone;
- 10 (32) Levomoramide;
- 11 (33) Levophenacymorphan;
- 12 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
- 13 piperidyl]-N-phenylpropanamide);
- 14 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
- 15 4-piperidinyl]-N-phenylpropanamide);
- 16 (36) Morpheridine;
- 17 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 18 (38) Noracymethadol;
- 19 (39) Norlevorphanol;
- 20 (40) Normethadone;
- 21 (41) Norpipanone;

- 1 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
2 phenethyl)-4-piperidinyl] propanamide;
- 3 (43) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
- 4 (44) Phenadoxone;
- 5 (45) Phenampromide;
- 6 (46) Phenomorphan;
- 7 (47) Phenoperidine;
- 8 (48) Piritramide;
- 9 (49) Proheptazine;
- 10 (50) Properidine;
- 11 (51) Propiram;
- 12 (52) Racemoramide;
- 13 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
14 piperidinyl]-propanamide);
- 15 (54) Tilidine;
- 16 (55) Trimeperidine;
- 17 (56) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
18 (benzylfentanyl), its optical isomers, salts, and
19 salts of isomers; and
- 20 (57) N-[1-(2-thienyl)methyl-4-piperidyl]-N-
21 phenylpropanamide (thenylfentanyl), its optical
22 isomers, salts, and salts of isomers.

1 (c) Any of the following opium derivatives, their salts,
2 isomers, and salts of isomers, unless specifically excepted,
3 whenever the existence of these salts, isomers, and salts of
4 isomers is possible within the specific chemical designation:

- 5 (1) Acetorphine;
- 6 (2) Acetyldihydrocodeine;
- 7 (3) Benzylmorphine;
- 8 (4) Codeine methylbromide;
- 9 (5) Codeine-N-Oxide;
- 10 (6) Cyprenorphine;
- 11 (7) Desomorphine;
- 12 (8) Dihydromorphine;
- 13 (9) Drotebanol;
- 14 (10) Etorphine;
- 15 (11) Heroin;
- 16 (12) Hydromorphinol;
- 17 (13) Methyldesorphine;
- 18 (14) Methyldihydromorphine;
- 19 (15) Morphine methylbromide;
- 20 (16) Morphine methylsulfonate;
- 21 (17) Morphine-N-Oxide;
- 22 (18) Myrophine;

1 (19) Nicocodeine;

2 (20) Nicomorphine;

3 (21) Normorphine;

4 (22) Phoclodine;

5 (23) Thebacon.

6 (d) Any material, compound, mixture, or preparation that
7 contains any quantity of the following hallucinogenic
8 substances, their salts, isomers, and salts of isomers, unless
9 specifically excepted, whenever the existence of these salts,
10 isomers, and salts of isomers is possible within the specific
11 chemical designation:

12 (1) Alpha-ethyltryptamine (AET);

13 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);

14 (3) 2,5-dimethoxyamphetamine (2,5-DMA);

15 (4) 3,4-methylenedioxy amphetamine;

16 (5) 3,4-methylenedioxymethamphetamine (MDMA);

17 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
18 MDA);

19 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);

20 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;

21 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);

22 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);

- 1 (11) 3,4,5-trimethoxy amphetamine;
- 2 (12) Bufotenine;
- 3 (13) 4-methoxyamphetamine (PMA);
- 4 (14) Diethyltryptamine;
- 5 (15) Dimethyltryptamine;
- 6 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 7 (17) Gamma hydroxybutyrate (GHB) (some other names include
- 8 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
- 9 hydroxybutanoic acid; sodium oxybate; sodium
- 10 oxybutyrate);
- 11 (18) Ibogaine;
- 12 (19) Lysergic acid diethylamide;
- 13 (20) Marijuana;
- 14 (21) Parahexyl;
- 15 (22) Mescaline;
- 16 (23) Peyote;
- 17 (24) N-ethyl-3-piperidyl benzilate;
- 18 (25) N-methyl-3-piperidyl benzilate;
- 19 (26) Psilocybin;
- 20 (27) Psilocyn;
- 21 (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);

1 ~~[(29) Tetrahydrocannabinols; meaning tetrahydrocannabinols~~
2 ~~naturally contained in a plant of the genus Cannabis~~
3 ~~(cannabis plant), as well as synthetic equivalents of~~
4 ~~the substances contained in the cannabis plant, or in~~
5 ~~the resinous extractives of such plant, or synthetic~~
6 ~~substances, derivatives, and their isomers with~~
7 ~~similar chemical structure and pharmacological~~
8 ~~activity to those substances contained in the plant,~~
9 ~~such as the following:~~

10 ~~(A) 1 cis or trans tetrahydrocannabinol, and their~~
11 ~~optical isomers;~~

12 ~~(B) 6 cis or trans tetrahydrocannabinol, and their~~
13 ~~optical isomers; and~~

14 ~~(C) 3,4 cis or trans tetrahydrocannabinol, and its~~
15 ~~optical isomers.~~

16 ~~(Since nomenclature of these substances is not~~
17 ~~internationally standardized, compounds of these~~
18 ~~structures, regardless of numerical designation of~~
19 ~~atomic positions, are covered);~~

20 ~~(30)]~~ (29) Ethylamine analog of phencyclidine (PCE);

21 ~~(31)]~~ (30) Pyrrolidine analog of phencyclidine (PCPy,
22 PHP);

- 1 [~~(32)~~] (31) Thiophene analog of phencyclidine (TPCP; TCP);
- 2 [~~(33)~~] (32) Gamma-butyrolactone, including butyrolactone;
- 3 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 4 dihydro; dihydro-2(3H)-furanone; tetrahydro-2-
- 5 furanone; 1,2-butanolide; 1,4-butanolide; 4-
- 6 butanolide; gamma-hydroxybutyric acid lactone; 3-
- 7 hydroxybutyric acid lactone and 4-hydroxybutanoic acid
- 8 lactone with Chemical Abstract Service number 96-48-0
- 9 when any such substance is intended for human
- 10 ingestion;
- 11 [~~(34)~~] (33) 1,4 butanediol, including butanediol; butane-
- 12 1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-
- 13 dihydroxybutane; 1,4- tetramethylene glycol;
- 14 tetramethylene glycol; tetramethylene 1,4- diol with
- 15 Chemical Abstract Service number 110-63-4 when any
- 16 such substance is intended for human ingestion;
- 17 [~~(35)~~] (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine
- 18 (2C-T-7), its optical isomers, salts, and salts of
- 19 isomers;
- 20 [~~(36)~~] (35) N-benzylpiperazine (BZP; 1-benzylpiperazine)
- 21 its optical isomers, salts, and salts of isomers;

- 1 [~~(37)~~] (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP),
2 its optical isomers, salts, and salts of isomers;
- 3 [~~(38)~~] (37) Alpha-methyltryptamine (AMT), its isomers,
4 salts, and salts of isomers;
- 5 [~~(39)~~] (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-
6 DIPT), its isomers, salts, and salts of isomers;
- 7 [~~(40)~~] (39) Salvia divinorum;
- 8 [~~(41)~~] (40) Salvinorin A;
- 9 [~~(42)~~] (41) Divinorin A;
- 10 [~~(43)~~] ~~Mephedrone (2-methylamino-1-p-tolylpropan-1-one)~~
11 ~~also known as 4-methylmethcathinone (4-MMC),~~
12 ~~methylephedrone or MMCAT;~~
- 13 ~~(44) Methylendioxypropylvalerone (MDPV, MDPK);~~
- 14 ~~(45) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-~~
15 ~~methyloctan-2-yl)-6a,7,10,10a-~~
16 ~~tetrahydrobenzo[e]chromen-1-ol, (another trade name is~~
17 ~~HU-210);~~
- 18 ~~(46) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-~~
19 ~~yl)phenol), (other trade names include CP 47,497 and~~
20 ~~dimethyloctyl homologues);~~
- 21 ~~(47) 1-Pentyl-3-(1-naphthoyl)indole, (another trade name is~~
22 ~~JWH-018);~~

H.B. NO. 2600

1 ~~(48) 1-Butyl-3-(1-naphthoyl)indole, (another trade name is~~
2 ~~JWH-073; and~~

3 ~~(49) Cannabicyclohexanol.] and~~

4 (42) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some
5 trade or other names: 5-methoxy-3-[2-
6 (dimethylamino)ethyl]indole; 5-MeO-DMT)."

7 (e) Depressants. Unless specifically excepted, the
8 schedule shall include any material, compound, mixture, or
9 preparation which contains any quantity of the substance:

10 (1) Mecloqualone; or

11 (2) Methaqualone.

12 (f) Stimulants. Unless specifically excepted or unless
13 listed in another schedule, any material, compound, mixture, or
14 preparation which contains any quantity of the following
15 substances having a stimulant effect on the central nervous
16 system, including its salts, isomers, and salts of isomers:

17 (1) Aminorex;

18 (2) Cathinone;

19 (3) Fenethylamine;

20 (4) Methcathinone;

21 (5) N-ethylamphetamine;

22 (6) 4-methylaminorex;

H.B. NO. 2600

1 (7) N,N-dimethylamphetamine[±]; and

2 (8) Substituted cathinones, any compound, except bupropion

3 or compounds listed under a different schedule,

4 structurally derived from 2-aminopropan-1-one by

5 substitution at the 1-position with either phenyl,

6 naphthyl, or thiophene ring systems, whether or not

7 the compound is further modified in any of the

8 following ways:

9 (A) By substitution in the ring system to any extent

10 with alkyl, alkylendioxy, alkoxy, haloalkyl,

11 hydroxyl, or halide substituents, whether or not

12 further substituted in the ring system by one or

13 more other univalent substituents;

14 (B) By substitution at the 3-position with an acyclic

15 alkyl substituent; or

16 (C) By substitution at the 2-amino nitrogen atom with

17 alkyl, dialkyl, benzyl, or methoxybenzyl groups,

18 or by inclusion of the 2-amino nitrogen atom in a

19 cyclic structure.

20 Some other trade names: Mephedrone (2-methylamino-1-

21 p-tolylpropan-1-one), also known as 4-

22 methylmethcathinone (4-MMC), methylephedrone or MMCAT;

1 Methylenedioxypropylone (MDPV, MDPK); and methylene
2 or 3,4-methylenedioxypropylone.

3 (g) Any of the following cannabinoids, their salts,
4 isomers and salts of isomers, unless specifically excepted,
5 whenever the existence of these salts, isomers and salts of
6 isomers is possible within the specific chemical designation:

7 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
8 naturally contained in a plant of the genus Cannabis
9 (cannabis plant), as well as synthetic equivalents of
10 the substances contained in the plant, or in the
11 resinous extractives of Cannabis, sp. or synthetic
12 substances, derivatives, and their isomers with
13 similar chemical structure and pharmacological
14 activity to those substances contained in the plant,
15 such as the following: Delta 1 cis or trans
16 tetrahydrocannabinol, and their optical isomers; Delta
17 6 cis or trans tetrahydrocannabinol, and their optical
18 isomers; and Delta 3,4 cis or trans-
19 tetrahydrocannabinol, and its optical isomers (since
20 nomenclature of these substances is not
21 internationally standardized, compounds of these

- 1 structures, regardless of numerical designation of
2 atomic positions, are covered);
- 3 (2) Naphthoylindoles; meaning any compound containing a 3-
4 (1-naphthoyl)indole structure with substitution at the
5 nitrogen atom of the indole ring by a alkyl,
6 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
8 morpholinyl)ethyl group, whether or not further
9 substituted in the indole ring to any extent and
10 whether or not substituted in the naphthyl ring to any
11 extent;
- 12 (3) Naphthylmethylinindoles; meaning any compound containing
13 a 1H-indol-3-yl-(1-naphthyl) methane structure with
14 substitution at the nitrogen atom of the indole ring
15 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
17 2-(4-morpholinyl) ethyl group whether or not further
18 substituted in the indole ring to any extent and
19 whether or not substituted in the naphthyl ring to any
20 extent;
- 21 (4) Naphthoylpyrroles; meaning any compound containing a
22 3-(1-naphthoyl)pyrrole structure with substitution at

- 1 the nitrogen atom of the pyrrole ring by a alkyl,
2 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
4 morpholinyl)ethyl group whether or not further
5 substituted in the pyrrole ring to any extent, whether
6 or not substituted in the naphthyl ring to any extent;
- 7 (5) Naphthylmethylindenes; meaning any compound containing
8 a naphthylideneindene structure with substitution at
9 the 3-position of the indene ring by a alkyl,
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
11 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
12 ethyl group whether or not further substituted in the
13 indene ring to any extent, whether or not substituted
14 in the naphthyl ring to any extent;
- 15 (6) Phenylacetylindoles; meaning any compound containing a
16 3-phenylacetylindole structure with substitution at
17 the nitrogen atom of the indole ring by a alkyl,
18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
19 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
20 ethyl group whether or not further substituted in the
21 indole ring to any extent, whether or not substituted
22 in the phenyl ring to any extent;

- 1 (7) Cyclohexylphenols; meaning any compound containing a
2 2-(3-hydroxycyclohexyl) phenol structure with
3 substitution at the 5-position of the phenolic ring by
4 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
6 2-(4-morpholinyl) ethyl group whether or not
7 substituted in the cyclohexyl ring to any extent;
- 8 (8) Benzoylindoles; meaning any compound containing a 3-
9 (benzoyl) indole structure with substitution at the
10 nitrogen atom of the indole ring by a alkyl, aloalkyl,
11 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
12 methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
13 ethyl group whether or not further substituted in the
14 indole ring to any extent and whether or not
15 substituted in the phenyl ring to any extent;
- 16 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
17 pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
18 naphthalenylmethanone (another trade name is WIN
19 55,212-2); and
- 20 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-

1 methyloctan-2-yl)-6a,7,10,10a-
2 tetrahydrobenzo[c]chromen-1-ol (other trade names are:
3 HU-210 and HU-211)."

4 SECTION 2. Section 329-16, Hawaii Revised Statutes, is
5 amended by amending subsection (c) to read as follows:

6 "(c) Any of the following opiates, including their
7 isomers, esters, ethers, salts, and salts of isomers, whenever
8 the existence of these isomers, esters, ethers, and salts is
9 possible within the specific chemical designation:

- 10 (1) Alfentanil;
- 11 (2) Alphaprodine;
- 12 (3) Anileridine;
- 13 (4) Bezitramide;
- 14 (5) Bulk Dextropropoxyphene (nondosage form);
- 15 (6) Carfentanil;
- 16 (7) Dihydrocodeine;
- 17 (8) Diphenoxylate;
- 18 (9) Fentanyl;
- 19 (10) Isomethadone;
- 20 (11) Levo-alphaacetylmethadol (LAAM);
- 21 (12) Levomethorphan;
- 22 (13) Levorphanol;

- 1 (14) Metazocine;
- 2 (15) Methadone;
- 3 (16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-
- 4 diphenyl butane;
- 5 (17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-
- 6 diphenyl-propane-carboxylic acid;
- 7 (18) Pethidine (Meperidine);
- 8 (19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-
- 9 phenylpiperidine;
- 10 (20) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
- 11 carboxylate;
- 12 (21) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-
- 13 4-carboxylic acid;
- 14 (22) Phenazocine;
- 15 (23) Piminodine;
- 16 (24) Racemethorphan;
- 17 (25) Racemorphan;
- 18 (26) Remifentanil;
- 19 (27) Sufentanil; and
- 20 (28) Tapentadol [~~and~~
- 21 ~~(29) 4-anilino-N-phenethyl-4-piperidine (ANPP)] ."~~

1 SECTION 3. Section 329-16, Hawaii Revised Statutes, is
2 amended by amending subsection (f) to read as follows:

3 "(f) Immediate precursor. Unless listed in another
4 schedule, any material, compound, mixture, or preparation which
5 contains any quantity of the following substances:

6 (1) Immediate precursor to amphetamine and
7 methamphetamine:

8 (A) Phenylacetone, phenyl-2-propanone (P2P), benzyl
9 methyl ketone, methyl benzyl ketone [~~or~~];

10 (2) Immediate precursors to phencyclidine (PCP):

11 (A) 1-phenylcyclohexylamine; and

12 (B) 1-piperidinocyclohexanecarbonitrile (PCC) [~~+~~]; or

13 (3) Immediate precursor to Fentanyl:

14 (A) 4-anilino-N-phenethyl-4-piperidine (ANPP)."

15 SECTION 4. Section 329-32, Hawaii Revised Statutes, is
16 amended by amending subsection (e) to read as follows:

17 "(e) A separate registration shall be required at each
18 principal place of business or professional practice where the
19 applicant manufactures, distributes, prescribes, or dispenses
20 controlled substances [~~7~~] or recommends the medical use of
21 marijuana, except an office used by a practitioner (who is
22 registered at another location) where controlled substances are

H.B. NO. 2600

1 prescribed but neither administered nor otherwise dispensed as a
2 regular part of the professional practice of the practitioner at
3 such office, and where no supplies of controlled substances are
4 maintained."

5 SECTION 5. Statutory material to be repealed is bracketed
6 and stricken. New statutory material is underscored.

7 SECTION 6. This Act shall take effect upon its approval.

8
9 INTRODUCED BY: _____

Calvin K. Boy

10 BY REQUEST

11 JAN 23 2012

H.B. NO. 2600

Report Title:

Controlled Substances

Description:

Updates chapter 329, Hawaii Revised Statutes, to make it consistent with federal laws on controlled substances; and amends section 329-32 relating to the registration requirements for physicians who utilize Hawaii's Medical Use of Marijuana Program.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

JUSTIFICATION SHEET

DEPARTMENT: Public Safety

TITLE: A BILL FOR AN ACT RELATING TO CONTROLLED SUBSTANCES.

PURPOSE: Update chapter 329, Hawaii Revised Statutes (HRS), to make it consistent with federal laws on controlled substances; amend section 329-32 relating to registration requirements for physicians who utilize Hawaii's Medical Use of Marijuana Program.

MEANS: Amend sections 329-14, 329-16(c) and (f), and 329-32(e), HRS.

JUSTIFICATION: Proposed amendments to chapter 329, HRS, will accomplish the following:

- (1) Update Hawaii's Uniform Controlled Substance Act, chapter 329, HRS, to be consistent with amendments made to the Federal Controlled Substance Act, 75 Federal Register 79296, by adding the hallucinogenic substance 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), to Schedule I as required by section 329-11(d), HRS.
- (2) Amend Hawaii's Uniform Controlled Substance Act, section 329-14(d), HRS, relating to Schedule I hallucinogenic substances, by deleting the class of drugs identified as cannabinoids and assign this class of drugs its own designation under section 329-14(g). This amendment will encompass all cannabinoid drugs as well as the synthetic cannabinoids recently scheduled by the State and federal government as Schedule I hallucinogenic controlled substances. The bill uses a general chemical class approach intended to prevent manufacturers from simply adding an isomer onto an existing controlled substance and

thereby making it a new non-controlled compound.

- (3) Amend Hawaii's Uniform Controlled Substance Act, section 329-14, HRS, by deleting the drugs classified as synthetic cathinones (MMCAT, MDPV and methylone) from section 329-14(d) and adding them to section 329-14(f), schedule I stimulant substances, to be consistent with recent federal emergency scheduling of these substances. The bill uses a general chemical class approach intended to prevent manufacturers from simply adding an isomer onto an existing controlled substance and thereby making it a new non-controlled compound.
- (4) Update Hawaii's Uniform Controlled Substance Act, chapter 329, HRS, to be consistent with changes made to the Federal Controlled Substance Act, 75 Federal Register 37296, by moving the narcotic drug 4-ANILINO-N-PHENETHYL-4-PIPERIDINE (ANPP) from section 329-16(c) to (f), as a precursor to Fentanyl.
- (5) Amend section 329-32(e), HRS, by requiring that all locations where patients are treated and where a physician makes a recommendation to his patient to utilize marijuana for medical purposes be registered with the department.

Impact on the public: This bill is intended to protect the public by updating Hawaii's controlled substance schedules to be consistent with that of federal law and to add language to the statutes to prevent an individual from simply adding an isomer onto an existing controlled substance and thereby make it a new non-controlled drug.

Impact on the department and other agencies: These proposed amendments would assist the Department of Public Safety's Narcotics

Enforcement Division, and federal, state, and county law enforcement agencies to address the growing problem of these new synthetic drugs.

GENERAL FUND: None.

OTHER FUNDS: None.

PPBS PROGRAM
DESIGNATION: PSD 502.

OTHER AFFECTED
AGENCIES: Department of Health's Food and Drug Branch, federal, state, and county law enforcement agencies.

EFFECTIVE DATE: Upon approval.